7544-75-4

Basic information

• Product Name: 2-AMINO-1-PYRROLINE HYDROCHLORIDE
• Synonyms: 2-AMINO-1-PYRROLINE HYDROCHLORIDE;4,5-Dihydro-3H-pyrrol-2-ylamine hydrochloride;2H-Pyrrol-5-amine, 3,4-dihydro-, hydrochloride (1:1);2-amino-4,5-dihydro-3H-pyrrole HCl salt;2H-Pyrrol-5-amine, 3,4-dihydro-, monohydrochloride;2-Aminopyrrolidine hydrochloride;3,4-Dihydro-2H-pyrrol-5-aMine hydrochloride;2-AMinopyrrolidine HCl
• CAS NO: 7544-75-4
• Molecular Formula: C₄H₈N₂*ClH
• Molecular Weight: 120.58066
• Product Categories: chemical
• Mol File: 7544-75-4.mol

Chemical Properties

• Melting Point: 171.0 to 175.0 °C
• Boiling Point: 211 °C at 760 mmHg
• Flash Point: 81.4 °C
• Appearance: /
• Vapor Pressure: 0.155mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-AMINO-1-PYRROLINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-1-PYRROLINE HYDROCHLORIDE(7544-75-4)
• EPA Substance Registry System: 2-AMINO-1-PYRROLINE HYDROCHLORIDE(7544-75-4)

Safety Data

• RIDADR: UN 1993 3/PG III
• HazardClass: 3
• PackingGroup: III
• Hazardous Substances Data: 7544-75-4(Hazardous Substances Data)

Usage

Uses

Used in Scientific Research:
2-Amino-1-pyrroline hydrochloride is used as a chemical intermediate for the synthesis of other organic compounds, playing a crucial role in various research applications.
Used in Laboratory Settings:
2-Amino-1-pyrroline hydrochloride is used as a reagent in controlled laboratory environments, where it aids in the development and testing of new chemical compounds and processes.
Used in Industrial Applications:
2-Amino-1-pyrroline hydrochloride is used as a component in the production of certain industrial chemicals, contributing to the manufacturing of various products.

InChI:InChI=1/C4H8N2.ClH/c5-4-2-1-3-6-4;/h1-3H2,(H2,5,6);1H

Upstream product

• 66996-69-8 2-Methoxypyrroline 
• 5264-35-7 2-methoxy-1-pyrroline 
• 628-20-6 4-Chlorobutyronitrile 
• 616-45-5 2-pyrrolidinon 

Downstream Products

• 107392-72-3 2-phenyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole 
• 133365-44-3 7,8-dihydro-6H-pyrrolo<1,2-a>-1,3,5-triazine-2,4(3H)-dione 
• 122454-71-1 2-(pyridin-4-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole 
• 101386-17-8 C₁₁H₁₃N₃O₃S 
• 408498-42-0 2-(pyridin-2-yl)-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole 
• 1221577-79-2 7,8-dihydro-3-methyl-2-(trifluoromethyl)pyrrolo[1,2-a]pyrimidin-4(6H)-one 
• 623564-38-5 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole-2-carbaldehyde 
• 1379426-02-4 C₁₀H₁₈N₂O₂ 
• 101386-19-0 C₁₁H₁₂ClN₃O₃S 
• 101386-18-9 C₁₂H₁₅N₃O₃S 

Relevant articles and documents

AN IMPROVED PROCESS FOR THE PREPARATION OF TIPIRACIL HYDROCHLORIDE AND INTERMEDIATES THEREOF

The present invention provides a process for the preparation of Tipiracil HCl of Formula (I) and intermediate thereof with improved yields and purities.

NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A

The present invention relates to compounds of the formula I and their salts etc. which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders. wherein Y1 and Y2 are adjacent atoms in Het1, which are independently selected from the group consisting of carbon and nitrogen; k is 0, 1, 2 or 3; Het1 is a bivalent monocyclic 5- or 6-membered heteroaromatic radical, having 1, 2 or 3 heteroatoms or heteroatom moieties selected from O, S, N and N—Ra as ring members, or a bivalent fused bicyclic 8-, 9- or 10-membered heteroaromatic radical, having 1, 2, 3 or 4 heteroatoms or heteroatom moieties selected from O, S, N and N—Ra as ring members; Het2 is inter alia monocyclic 5- or 6-membered hetaryl, having 1, 2 or 3 heteroatoms or heteroatom moieties selected from O, S, N and N—R1a as ring members, Cyc is inter alia optionally substituted monocyclic 5- or 6-membered hetaryl or optionally substituted fused 8-, 9- or 10-membered bicyclic hetaryl; Ar is optionally substituted phenylene or optionally substituted bivalent 6-membered hetaryl; R is attached to a carbon atom of Het1 and inter alia-halogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy, C1-C6-fluoroalkyl, C1-C6-fluoroalkoxy, C3-C6-cycloalkyl etc.

HETEROBICYCLIC ALKYLTHIO-BRIDGED ISOXAZOLINES

Disclosed are compounds of Formula 1, N-oxides, and salts thereof, wherein J is and R1, R2, R3, R4, R5, R6, R7, R8a, R8b, R8c, G1, G2, G3, G4, G5, G6, Q1, Q2, Q3, Q4, W1, W2, Y1, Y2, Y3, m and n are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of a compound or a composition of the invention.

Identification of novel inhibitors of the transforming growth factor β1 (TGF-β1) type 1 receptor (ALK5)

Screening of our internal compound collection for inhibitors of the transforming growth factor β1 (TGF-β1) type I receptor (ALK5) identified several hits. Optimization of the dihydropyrroloimidazole hit 2 by introduction of a 2-pyridine and 3,4-methylenedioxyphenyl group gave 7, a selective ALK5 inhibitor. With this information, optimization of the triarylimidazole hit 8 gave the selective inhibitor 14, which inhibits TGF-β1-induced fibronectin mRNA formation while displaying no measurable cytotoxicity in the 48 h XTT assay.

Cyclic amidine analogs as inhibitors of nitric oxide synthase

Disclosed herein are compounds of Formula I STR1 and pharmaceutically acceptable salts thereof which have been found useful in the treatment of nitric oxide synthase mediated diseases and disorders, including neurodegenerative disorders, disorders of gastrointestinal motility and inflammation. These disease and disorders include hypotension, septic shock, toxic shock syndrom, hemodialysis, IL-2 therapy such as in cancer patients, cachexia, immunosuppression such as in transplant therapy, autoimmune and/or inflammatory indications including sunburn or psoriasis and respiratory conditions such as bronchitis, asthma, and acure respiratory distress (ARDS), myocarditis, heart failure, atherosclerosis, arthritis, rheumatoid arthritis, chronic or inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic lupus erythematosis (SLE), ocular conditions such as ocular hypertension and uveitis, type 1 diabetes, insulin-dependent diabetes mellitus and cystic fibrosis. Compounds of Formula I are also usful in the treatment of hypoxia, hyperbaric oxygen convulsions and toxicity, dementia, Sydenham's chorea, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, mulitple sclerosis, Korsakoff's disease, imbecility related to cerebral vessel disorder, ischemic brain edema, sleeping disorders, schizophrenia, depression, PMS, anxiety, drug addiction, pain, migraine, immune complex disease, as immunosupressive agents and for preventing or reversing tolerance to opiates and diazepines.